

STN Registry / Caplus Search Strategy

10/509,795

09/15/2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and
USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 FSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18 SEP 11 CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:21:53 ON 13 SEP 2006

=> fil reg
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:22:03 ON 13 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 12 SEP 2006 HIGHEST RN 906508-44-9
 DICTIONARY FILE UPDATES: 12 SEP 2006 HIGHEST RN 906508-44-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
 Uploading C:\Program Files\Stnexp\Queries\10509795\2.str




chain nodes :
 10 11 12 13 14 15 16
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 6-11 7-12 9-10 12-13 13-14 14-15 15-16
 ring bonds :
 1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
 exact/norm bonds :

2-7 3-9 6-11 7-8 8-9 12-13 13-14
 exact bonds :
 7-12 9-10 14-15 15-16
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
 12:>= minimum 0
 Connectivity :
 12:4 M minimum RC ring/chain
 Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Any
 Generic attributes :
 16:
 Saturation : Unsaturated
 Element Count :
 Node 16: Limited
 C,C6-14

L1 STRUCTURE UPLOADED

=> d
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

10/509,795

09/15/2006

SAMPLE SEARCH INITIATED 16:22:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 18267 TO ITERATE

10.9% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

8 ANSWERS


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 357248 TO 373432
PROJECTED ANSWERS: 949 TO 1973

L2 8 SEA SSS SAM L1

=> d scan

L2 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclopropanecarboxamide, N-[3-[(1E)-2-(3,4-difluorophenyl)ethenyl]-6-
fluoro-1H-indazol-5-yl]-1-hydroxy- (9CI)
MF C19 H14 F3 N3 O2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-Pyrrole-2-carboxamide, N-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-
1H-indazol-5-yl]-1-methyl- (9CI)
MF C21 H16 F2 N4 O


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzeneacetic acid, 4-[[[3-(4-fluorophenyl)-1H-indazol-5-yl]carbonyl]amino]- (9CI)
 MF C22 H16 F N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 11 full
 FULL SEARCH INITIATED 16:22:59 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 361743 TO ITERATE

100.0% PROCESSED 361743 ITERATIONS
 SEARCH TIME: 00.00.03

1405 ANSWERS

L3 1405 SEA SSS FUL L1

=> fil caplus			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	167.38	167.59	

FILE 'CAPLUS' ENTERED AT 16:23:12 ON 13 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 12 Sep 2006 (20060912/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 13
L4 64 L3

=> d ibib abs hitstr 1-64

L4 ANSWER 20 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:610427 CAPLUS <<LOGINID::20060913>>
 DOCUMENT NUMBER: 139:164790
 TITLE: Preparation of indazoles as protein kinase inhibitors
 INVENTOR(S): Binch, Hayley; Brenchley, Guy; Golec, Julian M. C.;
 Knegtel, Ronald; Mortimore, Michael; Patel, Sanjay;
 Rutherford, Alistair
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 156 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent ✓
 LANGUAGE: English ✓
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	102 (e)
WO 2003064397	A1	20030807	WO 2003-US2096	20030123	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2473986	AA	20030807	CA 2003-2473986	20030123	
US 2004009968	A1	20040115	US 2003-350806	20030123	
US 7041687	B2	20060509			
EP 1467972	A1	20041020	EP 2003-708869	20030123	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005524631	T2	20050818	JP 2003-564020	20030123	
CN 1812973	A	20060802	CN 2003-805612	20030123	
NO 2004003531	A	20041025	NO 2004-3531	20040824	
JP 2006176530	A2	20060706	JP 2006-1918	20060106	
PRIORITY APPLN. INFO.:			US 2002-351597P	P 20020125	
			JP 2003-564020	A3 20030123	
			WO 2003-US2096	W 20030123	

OTHER SOURCE(S): MARPAT 139:164790
 GI



AB The title compds. [I; R1 = halo, CN, (un)substituted NH₂, etc.; R2 = (CH₂)₂Ph, (un)substituted CH₂Ph, CH₂(1- or 2-naphthyl), etc.; V1-V3 = N, (un)substituted CH; with proviso] and pharmaceutically acceptable salts which are inhibitors of protein kinase, particularly inhibitors of AKT,


Binch 2/12

10/509, 795


09/13/2006

PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders, were prepared. Thus, reacting 5-aminoindazole with 3-chlorophenylacetic acid in the presence of HOBt, EDC.HCl and N-methylmorpholine in DMF afforded 42% 2-(3-chlorophenyl)-N-(1H-indazol-5-yl)acetamide which showed Ki of < 1 μ M against ROCK kinase.


RN 574726-65-1 CAPLUS

CN Benzeneacetamide, α -(2-aminoethyl)-N-[3-(phenylamino)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

RN 574727-05-2 CAPLUS


CN Benzeneacetamide, α -(2-aminoethyl)-3,4-dichloro-N-[3-[(3-phenylmethoxy)phenyl]amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

RN 574727-06-3 CAPLUS


CN Benzeneacetamide, α -(2-aminoethyl)-3,4-dichloro-N-[3-[(3-chlorophenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

RN 574727-07-4 CAPLUS


CN Benzeneacetamide, α -(2-aminoethyl)-3,4-dichloro-N-[3-[(4-chlorophenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 574727-08-5 CAPLUS


CN Benzeneacetamide, α -(2-aminoethyl)-3,4-dichloro-N-[3-[(4-cyanophenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

RN 574727-09-6 CAPLUS


CN Benzeneacetamide, α -(2-aminoethyl)-3,4-dichloro-N-[3-[(3-cyanophenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

RN 574727-10-9 CAPLUS


CN Benzeneacetamide, α -(2-aminoethyl)-N-[3-[(4-bromophenyl)amino]-1H-indazol-5-yl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 574727-66-5 CAPLUS

CN Benzeneacetamide, α -(2-aminoethyl)-3,4-dichloro-N-[3-[(3-methylphenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

RN 574727-67-6 CAPLUS

CN Benzeneacetamide, α -(2-aminoethyl)-3,4-dichloro-N-[3-[(3-fluorophenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

RN 574727-87-0 CAPLUS

CN Benzeneacetamide, α -(aminomethyl)-3,4-dichloro-N-[3-[(3-cyanophenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Bind 7/2

10/509, 795

09/13/2006


RN 574728-77-1 CAPLUS

CN Benzeneacetamide, α -(2-aminoethyl)-N-[3-[(3-chlorophenyl)amino]-1H-indazol-5-yl]-3-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 574728-76-0


CMF C24 H24 Cl N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 574728-79-3 CAPLUS

CN Benzeneacetamide, N-[3-[(3-(aminocarbonyl)phenyl)amino]-1H-indazol-5-yl]- α -(2-aminoethyl)-3-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 574728-78-2


CMF C25 H26 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 574728-81-7 CAPLUS
CN Benzeneacetamide, α -(2-aminoethyl)-N-[3-[(3-cyanophenyl)amino]-1H-indazol-5-yl]-3-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 574728-80-6
CMF C25 H24 N6 O2

CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 574728-88-4 CAPLUS
 CN Benzeneacetamide, α -(2-aminoethyl)-N-[3-[(3-fluorophenyl)amino]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 574728-96-4 CAPLUS
 CN Benzeneacetamide, α -(2-aminoethyl)-3-chloro-N-[3-[(3-cyanophenyl)amino]-1H-indazol-5-yl]-2,6-difluoro-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 574728-97-5 CAPLUS
 CN Benzeneacetamide, α -(2-aminoethyl)-3-chloro-N-[3-[(3-cyanophenyl)amino]-1H-indazol-5-yl]-2,6-difluoro-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Bind 1012

10/509, 795

09/13/2006



Z = optionally subst. C_{1-6}
Alkylene group

Bind 11/12


10/509, 795

09/13/2006

RN 574729-03-6 CAPLUS

CN Benzeneacetamide, α -(2-aminoethyl)-N-[3-[(3-cyanophenyl)amino]-1H-indazol-5-yl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574729-04-7 CAPLUS

CN Benzeneacetamide, α -(2-aminoethyl)-N-[3-[(3-cyanophenyl)amino]-1H-indazol-5-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Binch 12/12

10/509, 795

09/13/2006

RN 574729-29-6 CAPLUS


CN 1H-Indazol-3-amine, 5-nitro-N-phenyl- (9CI) (CA INDEX NAME)



L = bond
X = bond
Y = Nitro

RN 574729-31-0 CAPLUS

CN Benzonitrile, 3-[(5-nitro-1H-indazol-3-yl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:107318 CAPLUS <<LOGINID::20060913>>
 DOCUMENT NUMBER: 136:151163
 TITLE: Preparation of indazole derivatives as JNK enzyme
 inhibitors
 INVENTOR(S): Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven
 T.
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 412 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010137	A2	20020207	WO 2001-US23890	20010730
WO 2002010137	C2	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417650	AA	20020207	CA 2001-2417650	20010730
EP 1313711	A2	20030528	EP 2001-957332	20010730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513882	T2	20040513	JP 2002-516269	20010730
NZ 524045	A	20040730	NZ 2001-524045	20010730
ZA 2003000886	A	20050309	ZA 2003-886	20030131
PRIORITY APPLN. INFO.:			US 2000-221799P	P 20000731
			WO 2001-US23890	W 20010730

OTHER SOURCE(S): MARPAT 136:151163
 AB Indazole derivs., 3-R1A-5-R2-1H-indazoles (1), having activity as selective inhibitors of JNK are disclosed. In 1: A is a direct bond, -(CH₂)_a, -(CH₂)_bCH:CH(CH₂)_c, or -(CH₂)_bC.tplbond.C(CH₂)_c; R₁ is aryl, heteroaryl or heterocycle fused to Ph, each being optionally substituted with 1-4 R₃; R₂ is -R₃, -R₄, -(CH₂)_bC(O)R₅, -(CH₂)_bC(:O)OR₅, -(CH₂)_bC(O)NR₅R₆, -(CH₂)_bC(O)NR₅(CH₂)_cC(O)R₆, -(CH₂)_bNR₅C(O)R₆, -(CH₂)_bNR₅C(O)NR₆R₇, -(CH₂)_bNR₅R₆, -(CH₂)_bOR₅, -(CH₂)_bSO_dR₅ or -(CH₂)_bSO₂NR₅R₆. A is 1-6; b and c are the same or different and are 0-4; d is 0-2. R₃ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(O)OR₈, -C(O)R₈, -C(O)NR₈R₉, -C(O)NR₈OR₉, -SO₂NR₈R₉, -NR₈SO₂R₉, -CN, -NO₂, -NR₈R₉, -NR₈C(O)R₉, -NR₈C(O)(CH₂)_bOR₉, -NR₈C(O)(CH₂)_bR₉, -O(CH₂)_bNR₅R₉, or heterocycle fused to Ph. R₄ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with 1-4 R₃, or R₄ is halogen or hydroxy. R₅, R₆ and R₇ are the same or different and are H, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R₅, R₆ and R₇ are optionally substituted with 1-4 R₃. R₈ and R₉ are the same or different and at each occurrence independently H, alkyl, aryl,

arylalkyl, heterocycle, or heterocyclealkyl, or R8 and R9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R8, R9, and R8 and R9 taken together to form a heterocycle are optionally substituted with 1-4 R3 with the proviso that: when A is a direct bond and R1 is Ph, R2 is not Me, methoxy, C(O)CH₃ or C(O)H; when A is a direct bond and R1 is 4-Me-Ph, R2 is not Me; when A is a direct bond and R1 is 4-F-Ph, R2 is not trifluoromethyl; when A is a direct bond or -C.tpbond.C- and R1 is Ph, R2 is not -COOEt; and when A is a direct bond and R1 is 6,7-dimethoxyisoquinolin-1-yl, R2 is not hydroxy. Such compds. have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds. Many of the claimed compds. have IC₅₀ values $\leq 0.5 \mu\text{M}$ in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of preparation are not claimed, >400 example prepn. are included.

25/64

Bhagwat 3/3


10/509, 795

09/13/2006

RN 395102-15-5 CAPLUS

CN 1H-Indazole-5-carbonitrile, 3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



L4 ANSWER 26 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:545668 CAPLUS <<LOGINID::20060913>>
 DOCUMENT NUMBER: 135:137505
 TITLE: Synthesis of disubstituted indazole compounds as
 cyclin dependent kinase inhibitors and methods for
 inhibiting cell proliferation
 INVENTOR(S): Reich, Siegfried Heinz; Bleckman, Ted Michael;
 Kephart, Susan Elizabeth; Romines, William Henry, III;
 Wallace, Michael B.
 PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 183 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053268	A2	20010726	WO 2001-US1477	20010118
WO 2001053268	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2388885	AA	20010726	CA 2001-2388885	20010118
EP 1250326	A2	20021023	EP 2001-942620	20010118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002161022	A1	20021031	US 2001-761656	20010118
US 6555539	B2	20030429		
BR 2001007783	A	20021119	BR 2001-7783	20010118
JP 2003520273	T2	20030702	JP 2001-553270	20010118
EE 200200398	A	20031015	EE 2002-398	20010118
NZ 518531	A	20040924	NZ 2001-518531	20010118
ZA 2002003040	A	20030811	ZA 2002-3040	20020417
NO 2002002117	A	20020916	NO 2002-2117	20020503
BG 107011	A	20030430	BG 2002-107011	20020816
US 2003139463	A1	20030724	US 2002-291158	20021108
US 6919461	B2	20050719		
US 2005239855	A1	20051027	US 2005-112423	20050422
US 2006111322	A1	20060525	US 2006-329303	20060110
PRIORITY APPLN. INFO.:			US 2000-176484P	P 20000118
			US 2001-761656	A3 20010118
			WO 2001-US1477	W 20010118
			US 2002-291158	A3 20021108
			US 2005-112423	A3 20050422


OTHER SOURCE(S): MARPAT 135:137505
 GI

26/64

Reich p212

10/509, 795

09/13/2006



AB Title compds. I [R1 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.; R2 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.] were prepared Examples include over 90 synthetic examples and 8 bioassays. For instance, 5-amino-1H-indazole was converted to 5-chloro-3-iodo-1H-indazole by diazotization/chlorination (NaNO₂, HCl, 0°C/CuCl, 60°C) followed by iodination (I₂, NaOHaq). Protection as the N-SEM derivative and sequential Suzuki coupling with (E)-β-styreneboronic acid to the 3 position and phenylboronic acid to the 5-position yielded N-SEM derivative I (R1 = (E)-β-styrenyl; R2 = Ph). Deprotection with 3M HCl in EtOH at reflux afforded I (R1 = (E)-β-styrenyl; R2 = Ph; II). II had Ki = 1.7 μM for cdk4/cyclin D3 complex and Ki = 6.7 μM for chk1 protein kinase. Selected examples of I were also assayed for cytotoxicity (HCT 116 cell line, 69 examples). The invention is also directed to methods of treating cancer and disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis.


IT 351454-61-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

RN 351454-61-0 CAPLUS

CN 1H-Indazole, 3,5-bis[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 293758-67-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)


RN 293758-67-5 CAPLUS

CN 1H-Indazole, 5-nitro-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 62 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1965:3105 CAPLUS <<LOGINID::20060913>>
DOCUMENT NUMBER: 62:3105
ORIGINAL REFERENCE NO.: 62:561d-e
TITLE: Cyclic Amidines. XVII. 4-Imino-1,2,3-benzotriazines
AUTHOR(S): Partridge, M. W.; Stevens, M. F. G.
CORPORATE SOURCE: Univ. Nottingham, UK
SOURCE: Journal of the Chemical Society (1964), (Oct.), 3663-9
CODEN: JCSOA9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB cf. CA 59, 5170e. 4-Imino-1,2,3-benzotriazines (I) afford, on reduction, 3-aminoindazoles (e.g. II) and on decomposition in acid, 6-aminophenanthridines. The reactions of o-cyanophenyltriazenes were studied.
IT 840-12-0, 1H-Indazole, 5-methyl-3-p-toluidino-
(preparation of)
RN 840-12-0 CAPLUS
CN 1H-Indazol-3-amine, 5-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 56 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1973:136158 CAPLUS <<LOGINID::20060913>>
 DOCUMENT NUMBER: 78:136158
 TITLE: Synthesis of 3-arylaminoindazoles
 AUTHOR(S): Burmistrov, S. I.; Belykh, V. S.
 CORPORATE SOURCE: Dnepropetr. Khim.-Tekhnol. Inst. im. Dzerzhinskogo,
 Dnepropetrovsk, USSR
 SOURCE: Khimiya Geterotsiklichesikh Soedinenii (1973), (2),
 249-51
 CODEN: KGSSAQ; ISSN: 0132-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB The title compds. (I; R = H, Me, Cl, Br; R1 = 6-Me, 7-Cl, R2 = H, p-Me, p-Cl) were prepared in 91-8% yields by treatment of the 3-chloro- or 3-bromoindazole with the appropriate aromatic amine hydrohalide.
 IT 840-12-0P 40598-62-7P 40598-65-0P
 40598-67-2P 40598-68-3P 40598-69-4P
 40598-70-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 840-12-0 CAPLUS
 CN 1H-Indazol-3-amine, 5-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 40598-62-7 CAPLUS
 CN 1H-Indazol-3-amine, 5-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 40598-65-0 CAPLUS
 CN 1H-Indazol-3-amine, 5-methyl-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 40598-67-2 CAPLUS

CN 1H-Indazol-3-amine, 5-chloro-N-phenyl- (9CI) (CA INDEX NAME)




RN 40598-68-3 CAPLUS

CN 1H-Indazol-3-amine, N-(4-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 40598-69-4 CAPLUS

CN 1H-Indazol-3-amine, 5-bromo-N-phenyl- (9CI) (CA INDEX NAME)



RN 40598-70-7 CAPLUS

CN 1H-Indazol-3-amine, 5,7-dichloro-N-phenyl- (9CI) (CA INDEX NAME)

